PharmaTimes on 18. Nov. 2015
Merck Serono’s Erbitux and Amgen’s Vectibix cannot be used as first line therapies alongside chemotherapy for RAS wild-type metastatic colorectal cancer. While recognising their clinical effectiveness, the Institute’s Expert Review group concluded that even if they were provided for free they would still not be cost-effective, as the methodology used takes into account all the associated treatment costs, including the partner chemo regimens and hospital expenses.